Pride Complex

The document discussed the "PRIDE" complex, which referred to a range of skin side effects from epidermal growth factor receptor (EGFR) inhibitors used in cancer treatment, such as papulopustules and itching. It reported on two nonsmall cell lung cancer patients treated with gefitinib and erlotinib, who developed skin issues but no systemic toxicities or nail and hair abnormalities. Treatment with benzoyl peroxide, doxycycline, and emollients improved skin lesions within 2 weeks, although hair loss did not improve. The study emphasized the importance of managing these side effects without stopping cancer therapy.